Top 8 Asian Biopharma Clusters 2015
Friday, March 20, 2015
Asia’s emergence as a mecca for developing drugs, tools, and technologies began a generation ago, when Western companies began scrambling for countries where they could manufacture products for less than what was possible in Europe or the U.S.
But as biopharma has grown in Asia, so it has moved beyond manufacturing, to carrying out trials and R&D. From country to country on the continent, industry and government leaders now spend much time and attention promoting the need for innovation. And industry outside of Asia is taking notice, as it searches for growth beyond the traditional markets of the U.S., Europe, and Japan.
“The new generation of companies will focus on China, non-China Asia, the Middle East, Africa, and individual countries with large populations and increased healthcare spending,” G. Steven Burrill, CEO of Burrill LLC and Burrill Media, has predicted for 2015.
That focus, he added, will mean greater activity on foreign exchanges as companies in Europe and Asia raise money at home, capitalizing on strengthening economies and rising markets—and as Asian companies work to secure financing, both privately and on public markets.